
- /
- Supported exchanges
- / HM
- / IDP.HM
BIOGEN IDEC (IDP HM) stock market data APIs
BIOGEN IDEC Financial Data Overview
There is no Profile data available for IDP.HM.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get BIOGEN IDEC data using free add-ons & libraries
Get BIOGEN IDEC Fundamental Data
BIOGEN IDEC Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
BIOGEN IDEC News

Repligen, Bruker, Fortrea, Azenta, and Biogen Stocks Trade Down, What You Need To Know
What Happened? A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with...


Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States
Harrow to assume full commercial responsibility for BYOOVIZ® and OPUVIZ™ by the end of 2025 NASHVILLE, July 17, 2025--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharm...

Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States
Harrow will assume full commercial responsibility for BYOOVIZ® (ranibizumab-nuna) and OPUVIZ™ (aflibercept-yszy) upon full transition of Biogen’s commercialization rights back to Samsung Bioepis ...

The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association
STOCKHOLM, July 16, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the drug discovery research for lecanemab (product name Leqembi®), an anti...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.